Survival and immunomodulatory therapy in autoimmune disease-associated progressive pulmonary fibrosis: a multicenter registry (NEREA)

Clicks: 9
ID: 337587
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #326 of 335 articles by views in Lara D. Veeken

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 335 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVES: To assess the mortality rate related to interstitial lung disease (ILD) in autoimmune-ILD patients with progressive pulmonary fibrosis (PPF), and to evaluate the role of immunomodulatory therapy and other variables in the ILD-related mortality. METHODS: A longitudinal multicenter study was conducted in autoimmune ILD from 2005 to 2024 in Madrid. Patients were those enrolled in NEREA [pNEumology RhEumatology Autoinmune] registry who met PPF criteria. Main outcome was specific-cause mortality related to ILD. Independent variable: immunomodulatory therapy. Covariates: sociodemographic, clinical, other treatments. Survival techniques were used to estimate the cause specific mortality rate due to ILD (MR) and 95%CI, expressed per 100 patients-year. Fine-Gray competing risk regression models assessed the risk of immunomodulatory therapy on ILD-related mortality (results expressed as subhazard ratio (SHR) and 95%CI). RESULTS: Among 158 patients, 70.3% were on immunomodulatory therapy at PPF baseline, increasing to 81% during follow-up. 47 deaths were documented, and 79% of them were attributed to ILD-related causes with a MR of 6.2 [4.5-8.5]. MR was lower in patients who received immunomodulatory therapy, with a mean survival of 4.8 years in untreated patients and over 10 years in those who received treatment. Immunomodulatory therapy improved survival regardless other factors (SHR: 0.35 [0.19-0.66], p = 0.001). Additionally, a worse diffusing capacity for carbon monoxide (DLCO)% (<60), and to have emphysema independently increased the risk of ILD-related mortality. CONCLUSION: The study shows a considerable mortality directly attributable to ILD. Furthermore, it demonstrates a survival benefit in patients receiving immunomodulatory therapy regardless other factors.
Reference Key
openalex_W7224078503 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Cristina Vadillo, Cristina Matesanz, Asunción Nieto Barbero, Pablo Moreno-Fresneda, Olga Sanchez Pernaute, Fredeswinda Romero-Bueno, María Jesús Rodríguez Nieto, Rosalía Laporta, Hilda Godoy, Jesús Loarce, Juan Rigual, Leticia León, Lydia Abásolo
Journal Lara D. Veeken
Year 2026
DOI
10.1093/rheumatology/keag606
URL
https://doi.org/10.1093/rheumatology/keag606
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.